CN102781413A - 用于提供最大程度的恶臭和刺激控制的方法 - Google Patents
用于提供最大程度的恶臭和刺激控制的方法 Download PDFInfo
- Publication number
- CN102781413A CN102781413A CN2011800094395A CN201180009439A CN102781413A CN 102781413 A CN102781413 A CN 102781413A CN 2011800094395 A CN2011800094395 A CN 2011800094395A CN 201180009439 A CN201180009439 A CN 201180009439A CN 102781413 A CN102781413 A CN 102781413A
- Authority
- CN
- China
- Prior art keywords
- intimate
- zinc
- shaving
- cleansing product
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 31
- 230000007794 irritation Effects 0.000 title claims abstract description 5
- 239000002437 shaving preparation Substances 0.000 claims abstract description 22
- 150000003751 zinc Chemical class 0.000 claims description 17
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims description 8
- PICXIOQBANWBIZ-UHFFFAOYSA-N zinc;1-oxidopyridine-2-thione Chemical compound [Zn+2].[O-]N1C=CC=CC1=S.[O-]N1C=CC=CC1=S PICXIOQBANWBIZ-UHFFFAOYSA-N 0.000 claims description 5
- 239000011787 zinc oxide Substances 0.000 claims description 4
- 229940043810 zinc pyrithione Drugs 0.000 claims 4
- 239000000047 product Substances 0.000 description 46
- 230000001166 anti-perspirative effect Effects 0.000 description 34
- 239000003213 antiperspirant Substances 0.000 description 34
- 238000004140 cleaning Methods 0.000 description 32
- 239000000203 mixture Substances 0.000 description 28
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethanethiol Chemical compound CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 17
- 239000007787 solid Substances 0.000 description 17
- 239000002781 deodorant agent Substances 0.000 description 16
- 210000003491 skin Anatomy 0.000 description 12
- 239000000463 material Substances 0.000 description 11
- 238000012856 packing Methods 0.000 description 9
- 239000013543 active substance Substances 0.000 description 8
- 230000009286 beneficial effect Effects 0.000 description 7
- 230000000638 stimulation Effects 0.000 description 7
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 230000000845 anti-microbial effect Effects 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 5
- 239000006071 cream Substances 0.000 description 5
- -1 diisobutyl phenoxy group Chemical group 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 210000004209 hair Anatomy 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 4
- 239000002738 chelating agent Substances 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 239000004110 Zinc silicate Substances 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 229960003276 erythromycin Drugs 0.000 description 3
- 238000011010 flushing procedure Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- AGGKEGLBGGJEBZ-UHFFFAOYSA-N tetramethylenedisulfotetramine Chemical compound C1N(S2(=O)=O)CN3S(=O)(=O)N1CN2C3 AGGKEGLBGGJEBZ-UHFFFAOYSA-N 0.000 description 3
- 229910052725 zinc Inorganic materials 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- XSMMCTCMFDWXIX-UHFFFAOYSA-N zinc silicate Chemical compound [Zn+2].[O-][Si]([O-])=O XSMMCTCMFDWXIX-UHFFFAOYSA-N 0.000 description 3
- 235000019352 zinc silicate Nutrition 0.000 description 3
- DHPRQBPJLMKORJ-XRNKAMNCSA-N (4s,4as,5as,6s,12ar)-7-chloro-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O DHPRQBPJLMKORJ-XRNKAMNCSA-N 0.000 description 2
- TUATYNXRYJTQTQ-BVRBKCERSA-N 3,6-diamino-n-[[(2s,5s,8z,11s,15s)-15-amino-11-(2-amino-1,4,5,6-tetrahydropyrimidin-6-yl)-8-[(carbamoylamino)methylidene]-2-(hydroxymethyl)-3,6,9,12,16-pentaoxo-1,4,7,10,13-pentazacyclohexadec-5-yl]methyl]hexanamide;3,6-diamino-n-[[(2s,5s,8z,11s,15s)-15-a Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.N1C(=O)\C(=C\NC(N)=O)NC(=O)[C@H](CNC(=O)CC(N)CCCN)NC(=O)[C@H](C)NC(=O)[C@@H](N)CNC(=O)[C@@H]1C1NC(=N)NCC1.N1C(=O)\C(=C\NC(N)=O)NC(=O)[C@H](CNC(=O)CC(N)CCCN)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CNC(=O)[C@@H]1C1NC(=N)NCC1 TUATYNXRYJTQTQ-BVRBKCERSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-M Aminoacetate Chemical compound NCC([O-])=O DHMQDGOQFOQNFH-UHFFFAOYSA-M 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- 108010065839 Capreomycin Proteins 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 2
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 2
- 108010077895 Sarcosine Proteins 0.000 description 2
- 206010040880 Skin irritation Diseases 0.000 description 2
- QCWXUUIWCKQGHC-UHFFFAOYSA-N Zirconium Chemical compound [Zr] QCWXUUIWCKQGHC-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 239000001099 ammonium carbonate Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 2
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical class C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- AEUTYOVWOVBAKS-UWVGGRQHSA-N ethambutol Chemical compound CC[C@@H](CO)NCCN[C@@H](CC)CO AEUTYOVWOVBAKS-UWVGGRQHSA-N 0.000 description 2
- HSEMFIZWXHQJAE-UHFFFAOYSA-N hexadecanamide Chemical compound CCCCCCCCCCCCCCCC(N)=O HSEMFIZWXHQJAE-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 229960000282 metronidazole Drugs 0.000 description 2
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 2
- 229960002509 miconazole Drugs 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- XDRYMKDFEDOLFX-UHFFFAOYSA-N pentamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 XDRYMKDFEDOLFX-UHFFFAOYSA-N 0.000 description 2
- 229960004448 pentamidine Drugs 0.000 description 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 230000036556 skin irritation Effects 0.000 description 2
- 231100000475 skin irritation Toxicity 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 125000005207 tetraalkylammonium group Chemical group 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 229910000010 zinc carbonate Inorganic materials 0.000 description 2
- 229910052726 zirconium Inorganic materials 0.000 description 2
- CRDAMVZIKSXKFV-FBXUGWQNSA-N (2-cis,6-cis)-farnesol Chemical compound CC(C)=CCC\C(C)=C/CC\C(C)=C/CO CRDAMVZIKSXKFV-FBXUGWQNSA-N 0.000 description 1
- 239000000260 (2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-ol Substances 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- ZEUUPKVZFKBXPW-TWDWGCDDSA-N (2s,3r,4s,5s,6r)-4-amino-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,5s,6r)-3-amino-6-(aminomethyl)-5-hydroxyoxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-6-(hydroxymethyl)oxane-3,5-diol;sulfuric acid Chemical compound OS(O)(=O)=O.N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N ZEUUPKVZFKBXPW-TWDWGCDDSA-N 0.000 description 1
- VCOPTHOUUNAYKQ-WBTCAYNUSA-N (3s)-3,6-diamino-n-[[(2s,5s,8e,11s,15s)-15-amino-11-[(6r)-2-amino-1,4,5,6-tetrahydropyrimidin-6-yl]-8-[(carbamoylamino)methylidene]-2-(hydroxymethyl)-3,6,9,12,16-pentaoxo-1,4,7,10,13-pentazacyclohexadec-5-yl]methyl]hexanamide;(3s)-3,6-diamino-n-[[(2s,5s,8 Chemical compound N1C(=O)\C(=C/NC(N)=O)NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC(=O)[C@H](C)NC(=O)[C@@H](N)CNC(=O)[C@@H]1[C@@H]1NC(N)=NCC1.N1C(=O)\C(=C/NC(N)=O)NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CNC(=O)[C@@H]1[C@@H]1NC(N)=NCC1 VCOPTHOUUNAYKQ-WBTCAYNUSA-N 0.000 description 1
- XIYOPDCBBDCGOE-IWVLMIASSA-N (4s,4ar,5s,5ar,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methylidene-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C=C1C2=CC=CC(O)=C2C(O)=C2[C@@H]1[C@H](O)[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O XIYOPDCBBDCGOE-IWVLMIASSA-N 0.000 description 1
- VXPSARQTYDZXAO-CCHMMTNSSA-N (4s,4ar,5s,5ar,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methylidene-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide;hydron;chloride Chemical compound Cl.C=C1C2=CC=CC(O)=C2C(O)=C2[C@@H]1[C@H](O)[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O VXPSARQTYDZXAO-CCHMMTNSSA-N 0.000 description 1
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 1
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 1
- YCIHPQHVWDULOY-FMZCEJRJSA-N (4s,4as,5as,6s,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide;hydrochloride Chemical compound Cl.C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O YCIHPQHVWDULOY-FMZCEJRJSA-N 0.000 description 1
- PFNQVRZLDWYSCW-UHFFFAOYSA-N (fluoren-9-ylideneamino) n-naphthalen-1-ylcarbamate Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1=NOC(=O)NC1=CC=CC2=CC=CC=C12 PFNQVRZLDWYSCW-UHFFFAOYSA-N 0.000 description 1
- GWEHVDNNLFDJLR-UHFFFAOYSA-N 1,3-diphenylurea Chemical compound C=1C=CC=CC=1NC(=O)NC1=CC=CC=C1 GWEHVDNNLFDJLR-UHFFFAOYSA-N 0.000 description 1
- OAAZUWWNSYWWHG-UHFFFAOYSA-N 1-phenoxypropan-1-ol Chemical compound CCC(O)OC1=CC=CC=C1 OAAZUWWNSYWWHG-UHFFFAOYSA-N 0.000 description 1
- WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 description 1
- MPNXSZJPSVBLHP-UHFFFAOYSA-N 2-chloro-n-phenylpyridine-3-carboxamide Chemical compound ClC1=NC=CC=C1C(=O)NC1=CC=CC=C1 MPNXSZJPSVBLHP-UHFFFAOYSA-N 0.000 description 1
- WTJXVDPDEQKTCV-UHFFFAOYSA-N 4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide;hydron;chloride Chemical compound Cl.C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2C1CC1C(N(C)C)C(=O)C(C(N)=O)=C(O)C1(O)C2=O WTJXVDPDEQKTCV-UHFFFAOYSA-N 0.000 description 1
- YWMSSKBMOFPBDM-UHFFFAOYSA-N 4-carbamoylbenzenesulfonyl chloride Chemical compound NC(=O)C1=CC=C(S(Cl)(=O)=O)C=C1 YWMSSKBMOFPBDM-UHFFFAOYSA-N 0.000 description 1
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- WJLVQTJZDCGNJN-UHFFFAOYSA-N Chlorhexidine hydrochloride Chemical compound Cl.Cl.C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 WJLVQTJZDCGNJN-UHFFFAOYSA-N 0.000 description 1
- 239000004099 Chlortetracycline Substances 0.000 description 1
- YAVZHCFFUATPRK-YZPBMOCRSA-N Erythromycin stearate Chemical compound CCCCCCCCCCCCCCCCCC(O)=O.O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 YAVZHCFFUATPRK-YZPBMOCRSA-N 0.000 description 1
- KIWBPDUYBMNFTB-UHFFFAOYSA-N Ethyl hydrogen sulfate Chemical compound CCOS(O)(=O)=O KIWBPDUYBMNFTB-UHFFFAOYSA-N 0.000 description 1
- 235000005206 Hibiscus Nutrition 0.000 description 1
- 235000007185 Hibiscus lunariifolius Nutrition 0.000 description 1
- 244000048199 Hibiscus mutabilis Species 0.000 description 1
- 235000003973 Hibiscus mutabilis Nutrition 0.000 description 1
- 244000284380 Hibiscus rosa sinensis Species 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 235000019766 L-Lysine Nutrition 0.000 description 1
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N N-methylaminoacetic acid Natural products C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 239000004100 Oxytetracycline Substances 0.000 description 1
- UOZODPSAJZTQNH-UHFFFAOYSA-N Paromomycin II Natural products NC1C(O)C(O)C(CN)OC1OC1C(O)C(OC2C(C(N)CC(N)C2O)OC2C(C(O)C(O)C(CO)O2)N)OC1CO UOZODPSAJZTQNH-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 1
- 229910000611 Zinc aluminium Inorganic materials 0.000 description 1
- FMRLDPWIRHBCCC-UHFFFAOYSA-L Zinc carbonate Chemical compound [Zn+2].[O-]C([O-])=O FMRLDPWIRHBCCC-UHFFFAOYSA-L 0.000 description 1
- 239000005083 Zinc sulfide Substances 0.000 description 1
- KITLESRVTCYSKD-UHFFFAOYSA-N [Cl].C(C(O)C)(=O)O Chemical compound [Cl].C(C(O)C)(=O)O KITLESRVTCYSKD-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000011358 absorbing material Substances 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- HXFVOUUOTHJFPX-UHFFFAOYSA-N alumane;zinc Chemical compound [AlH3].[Zn] HXFVOUUOTHJFPX-UHFFFAOYSA-N 0.000 description 1
- DNEHKUCSURWDGO-UHFFFAOYSA-N aluminum sodium Chemical compound [Na].[Al] DNEHKUCSURWDGO-UHFFFAOYSA-N 0.000 description 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
- 229960001280 amantadine hydrochloride Drugs 0.000 description 1
- WOLHOYHSEKDWQH-UHFFFAOYSA-N amantadine hydrochloride Chemical compound [Cl-].C1C(C2)CC3CC2CC1([NH3+])C3 WOLHOYHSEKDWQH-UHFFFAOYSA-N 0.000 description 1
- 229960004821 amikacin Drugs 0.000 description 1
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 1
- 229960001656 amikacin sulfate Drugs 0.000 description 1
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 1
- 235000012501 ammonium carbonate Nutrition 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- CVSVTCORWBXHQV-UHFFFAOYSA-N anhydrous creatine Natural products NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- LLEMOWNGBBNAJR-UHFFFAOYSA-N biphenyl-2-ol Chemical compound OC1=CC=CC=C1C1=CC=CC=C1 LLEMOWNGBBNAJR-UHFFFAOYSA-N 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229960004602 capreomycin Drugs 0.000 description 1
- 229960002968 capreomycin sulfate Drugs 0.000 description 1
- CZPLANDPABRVHX-UHFFFAOYSA-N cascade blue Chemical compound C=1C2=CC=CC=C2C(NCC)=CC=1C(C=1C=CC(=CC=1)N(CC)CC)=C1C=CC(=[N+](CC)CC)C=C1 CZPLANDPABRVHX-UHFFFAOYSA-N 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 229960003333 chlorhexidine gluconate Drugs 0.000 description 1
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 1
- 229960004504 chlorhexidine hydrochloride Drugs 0.000 description 1
- CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 description 1
- 229960004475 chlortetracycline Drugs 0.000 description 1
- 235000019365 chlortetracycline Nutrition 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- 229960001200 clindamycin hydrochloride Drugs 0.000 description 1
- 229960004022 clotrimazole Drugs 0.000 description 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- HALQELOKLVRWRI-VDBOFHIQSA-N doxycycline hyclate Chemical compound O.[Cl-].[Cl-].CCO.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H]([NH+](C)C)[C@@H]1[C@H]2O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H]([NH+](C)C)[C@@H]1[C@H]2O HALQELOKLVRWRI-VDBOFHIQSA-N 0.000 description 1
- 229960001172 doxycycline hyclate Drugs 0.000 description 1
- 229960003203 erythromycin estolate Drugs 0.000 description 1
- AWMFUEJKWXESNL-JZBHMOKNSA-N erythromycin estolate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O.O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)OC(=O)CC)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AWMFUEJKWXESNL-JZBHMOKNSA-N 0.000 description 1
- 229960004142 erythromycin stearate Drugs 0.000 description 1
- 229960000285 ethambutol Drugs 0.000 description 1
- AUAHHJJRFHRVPV-BZDVOYDHSA-N ethambutol dihydrochloride Chemical compound [Cl-].[Cl-].CC[C@@H](CO)[NH2+]CC[NH2+][C@@H](CC)CO AUAHHJJRFHRVPV-BZDVOYDHSA-N 0.000 description 1
- 125000005448 ethoxyethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 229940043259 farnesol Drugs 0.000 description 1
- 229930002886 farnesol Natural products 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N ferric oxide Chemical compound O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 229960000443 hydrochloric acid Drugs 0.000 description 1
- POUMFISTNHIPTI-BOMBIWCESA-N hydron;(2s,4r)-n-[(1r,2r)-2-hydroxy-1-[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-methylsulfanyloxan-2-yl]propyl]-1-methyl-4-propylpyrrolidine-2-carboxamide;chloride Chemical compound Cl.CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 POUMFISTNHIPTI-BOMBIWCESA-N 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 230000037315 hyperhidrosis Effects 0.000 description 1
- CFUQBFQTFMOZBK-QUCCMNQESA-N ibazocine Chemical compound C12=CC(O)=CC=C2C[C@H]2N(CC=C(C)C)CC[C@]1(C)C2(C)C CFUQBFQTFMOZBK-QUCCMNQESA-N 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 229960004592 isopropanol Drugs 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- OOYGSFOGFJDDHP-KMCOLRRFSA-N kanamycin A sulfate Chemical compound OS(O)(=O)=O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N OOYGSFOGFJDDHP-KMCOLRRFSA-N 0.000 description 1
- 229960002064 kanamycin sulfate Drugs 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 229960005287 lincomycin Drugs 0.000 description 1
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 1
- 229960001595 lincomycin hydrochloride Drugs 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229940042016 methacycline Drugs 0.000 description 1
- 229940051860 methacycline hydrochloride Drugs 0.000 description 1
- 229960004023 minocycline Drugs 0.000 description 1
- 229960002421 minocycline hydrochloride Drugs 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 229960000808 netilmicin Drugs 0.000 description 1
- 229960004832 netilmicin sulfate Drugs 0.000 description 1
- ZBGPYVZLYBDXKO-HILBYHGXSA-N netilmycin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@]([C@H](NC)[C@@H](O)CO1)(C)O)NCC)[C@H]1OC(CN)=CC[C@H]1N ZBGPYVZLYBDXKO-HILBYHGXSA-N 0.000 description 1
- 229960001180 norfloxacin Drugs 0.000 description 1
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 1
- 239000001702 nutmeg Substances 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- 238000012946 outsourcing Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229960000625 oxytetracycline Drugs 0.000 description 1
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 1
- 235000019366 oxytetracycline Nutrition 0.000 description 1
- 229960004368 oxytetracycline hydrochloride Drugs 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 229960001914 paromomycin Drugs 0.000 description 1
- UOZODPSAJZTQNH-LSWIJEOBSA-N paromomycin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO UOZODPSAJZTQNH-LSWIJEOBSA-N 0.000 description 1
- 229960005065 paromomycin sulfate Drugs 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 231100000255 pathogenic effect Toxicity 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 229950001046 piroctone Drugs 0.000 description 1
- BTSZTGGZJQFALU-UHFFFAOYSA-N piroctone olamine Chemical compound NCCO.CC(C)(C)CC(C)CC1=CC(C)=CC(=O)N1O BTSZTGGZJQFALU-UHFFFAOYSA-N 0.000 description 1
- 108010019657 polymyxin drug combination nystatin neomycin dimethicone acetarsol Proteins 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- DQMZLTXERSFNPB-UHFFFAOYSA-N primidone Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NCNC1=O DQMZLTXERSFNPB-UHFFFAOYSA-N 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- FGVVTMRZYROCTH-UHFFFAOYSA-N pyridine-2-thiol N-oxide Chemical compound [O-][N+]1=CC=CC=C1S FGVVTMRZYROCTH-UHFFFAOYSA-N 0.000 description 1
- 229960002026 pyrithione Drugs 0.000 description 1
- 229960001141 pyrithione zinc Drugs 0.000 description 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229940043230 sarcosine Drugs 0.000 description 1
- 238000009991 scouring Methods 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 230000035943 smell Effects 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229940048098 sodium sarcosinate Drugs 0.000 description 1
- ZUFONQSOSYEWCN-UHFFFAOYSA-M sodium;2-(methylamino)acetate Chemical compound [Na+].CNCC([O-])=O ZUFONQSOSYEWCN-UHFFFAOYSA-M 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 229960002385 streptomycin sulfate Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229960000707 tobramycin Drugs 0.000 description 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 1
- 229960004477 tobramycin sulfate Drugs 0.000 description 1
- 229960004880 tolnaftate Drugs 0.000 description 1
- FUSNMLFNXJSCDI-UHFFFAOYSA-N tolnaftate Chemical compound C=1C=C2C=CC=CC2=CC=1OC(=S)N(C)C1=CC=CC(C)=C1 FUSNMLFNXJSCDI-UHFFFAOYSA-N 0.000 description 1
- CRDAMVZIKSXKFV-UHFFFAOYSA-N trans-Farnesol Natural products CC(C)=CCCC(C)=CCCC(C)=CCO CRDAMVZIKSXKFV-UHFFFAOYSA-N 0.000 description 1
- ICUTUKXCWQYESQ-UHFFFAOYSA-N triclocarban Chemical compound C1=CC(Cl)=CC=C1NC(=O)NC1=CC=C(Cl)C(Cl)=C1 ICUTUKXCWQYESQ-UHFFFAOYSA-N 0.000 description 1
- 229960001325 triclocarban Drugs 0.000 description 1
- 229960003500 triclosan Drugs 0.000 description 1
- MWKJTNBSKNUMFN-UHFFFAOYSA-N trifluoromethyltrimethylsilane Chemical compound C[Si](C)(C)C(F)(F)F MWKJTNBSKNUMFN-UHFFFAOYSA-N 0.000 description 1
- BIKXLKXABVUSMH-UHFFFAOYSA-N trizinc;diborate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]B([O-])[O-].[O-]B([O-])[O-] BIKXLKXABVUSMH-UHFFFAOYSA-N 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 125000002256 xylenyl group Chemical class C1(C(C=CC=C1)C)(C)* 0.000 description 1
- 239000011667 zinc carbonate Substances 0.000 description 1
- 235000004416 zinc carbonate Nutrition 0.000 description 1
- UGZADUVQMDAIAO-UHFFFAOYSA-L zinc hydroxide Chemical compound [OH-].[OH-].[Zn+2] UGZADUVQMDAIAO-UHFFFAOYSA-L 0.000 description 1
- 229940007718 zinc hydroxide Drugs 0.000 description 1
- 229910021511 zinc hydroxide Inorganic materials 0.000 description 1
- LRXTYHSAJDENHV-UHFFFAOYSA-H zinc phosphate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O LRXTYHSAJDENHV-UHFFFAOYSA-H 0.000 description 1
- 229910000165 zinc phosphate Inorganic materials 0.000 description 1
- 229910052984 zinc sulfide Inorganic materials 0.000 description 1
- KUPSFWMZXYCITC-UHFFFAOYSA-L zinc;phenol;sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O.OC1=CC=CC=C1 KUPSFWMZXYCITC-UHFFFAOYSA-L 0.000 description 1
- DRDVZXDWVBGGMH-UHFFFAOYSA-N zinc;sulfide Chemical compound [S-2].[Zn+2] DRDVZXDWVBGGMH-UHFFFAOYSA-N 0.000 description 1
- 150000003952 β-lactams Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q9/00—Preparations for removing hair or for aiding hair removal
- A61Q9/02—Shaving preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/27—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4933—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having sulfur as an exocyclic substituent, e.g. pyridinethione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/58—Metal complex; Coordination compounds
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Cosmetics (AREA)
- Detergent Compositions (AREA)
Abstract
本发明公开了一种用于降低对私密区的刺激的方法，所述方法包括：将私密清洁产品施用到私密区；将私密清洁产品从私密区冲洗掉；将剃刮制剂施用到私密区；剃刮私密区；其中所述私密清洁产品包含恶臭活性物质。
Description
发明领域
本发明涉及用于降低恶臭和剃刮刺激的消费品系列。
发明背景
从皮肤上剃除毛发是一项众所周知的美容活动。与剃须相关的一个持续的抱怨是由进行剃刮活动引起的刺激。克服这个问题的尝试包括提供附加的润滑剂、增稠剂、表面活性剂等。尽管许多这类系统提供了润滑和/或平滑剃刮，但皮肤刺激仍然是一个问题。
在面部，剃须后水材料减轻了一些刺激，但通常这些材料不适用于私密区。此外，私密区增加的复杂性使它们更适合微生物感染。此外，由于皮肤刺激表明皮肤受损，留下的皮肤更容易受到微生物的感染，这可能会导致附加的恶臭。已经尝试过许多降低刺激的方法，但没有获得满意的效果。因此，需要处理皮肤的刺激并用抗菌素处理皮肤。
发明概述
本发明涉及一种用于降低对私密区的刺激的方法，所述方法包括：将私密清洁产品施用到私密区；将私密清洁产品从私密区冲洗掉；将剃刮制剂施用到私密区；剃刮私密区；其中私密清洁产品包含恶臭活性物质。
发明详述
虽然本说明书以特别指出并清楚地要求保护本发明的权利要求作出结论，但据信通过以下说明将更好地理解本发明。
如本文所用，“包括”是指可加入其它步骤和/或成分。该术语包括术语“由...组成”和“基本上由...组成”。短语“基本上由...组成”是指本发明可包括附加步骤和/或成分，但只有当附加成分和/或步骤没有实质性地改变要求保护的发明或方法的基本和新型特性时。
除非另外指明，所有百分比、份数和比率均是按本发明的局部组合物的总重量计的，并且所有测量均在25℃下进行。除非另外指明，所有与所列成分相关的上述重量均是基于活性物质含量的，因此不包括可包含在市售原料中的载体或副产物。
本发明涉及一种用于降低对私密区的刺激的方法，所述方法包括：在私密区施用私密清洁产品；将私密清洁产品从私密区冲洗掉；在私密区施用剃刮制剂；在私密区剃刮；其中私密清洁产品包含恶臭活性物质。止汗剂或除臭剂能任选地被施用以提供附加的恶臭/湿度防护。
私密清洁产品
本文所述的私密清洁产品可包括不同种类的个人护理产品，包括但不限于沐浴剂、身体喷剂、乳液、霜膏等。视形式而定，所述私密清洁产品可被直接施用，放置在洗涤工具上，喷施等。洗涤工具包括海绵、毛巾、沐浴泡芙、刷子等。不受理论的束缚，据信洗涤工具提供了附加的擦洗机制，使得私密清洁产品能够进一步渗透到皮肤的毛孔和/或毛囊中。
所述私密清洁产品适宜被施用在私密区。本发明中的私密区包括腋下、大腿根部、足部、臀缝等。在一个实施方案中，所述私密清洁产品被施用在腋下。所述私密清洁产品的施用可以在淋浴或沐浴过程中进行。同样可以预期所述私密清洁产品的施用可以在非淋浴或沐浴场合进行，利用水槽进行施用和冲洗。
预期本发明的私密清洁产品在施用后被清除。典型的清除方法包括在淋浴或沐浴中冲洗，和/或利用洗涤工具。普通技术人员能够很容易确定一种有效地从私密区清除私密清洁产品的方法。
剃刮制剂
本发明的剃刮制剂包括基于非气溶胶和基于气溶胶的剃刮制剂。本发明的剃刮制剂有助于用剃刀或刀片去除皮肤上的毛发。剃刮制剂在皮肤与剃刀之间提供一个层，通过增加剃刮的舒适度来改进剃刮体验。该机制是通过添加增稠剂、润滑剂等来促进的。
所述剃刮制剂适于在私密区被施用。在一个实施方案中，本发明的剃刮制剂被用于腋下部位。剃刮制剂的施用可以在淋浴或沐浴期间进行。也可预期剃刮制剂的施用在非淋浴或沐浴期间进行，在水槽中施用和冲洗。
预期本发明的剃刮制剂在施用后被清除掉。典型的清除方法包括在淋浴或沐浴中冲洗，和/或利用洗涤工具。普通技术人员能够很容易确定一种有效地从私密区清除私密清洁产品的方法。
恶臭活性物质
在一个实施方案中，私密清洁产品和/或剃刮制剂包含恶臭活性物质。本发明的恶臭活性物质能提供抗微生物有益效果。此类恶臭活性物质能破坏微生物，从而阻止微生物的发育或阻止微生物的致病性作用。可将安全且有效量的恶臭活性物质添加到私密清洁产品中，按例如所述清洁产品的重量计，所述量为约0.001%至约10%，或约0.01%至约5%，或约0.05%至约2%，或约0.1%至约1%，或约0.3%至约0.7%，或约0.5%。
恶臭活性物质的实例包括β-内酰胺药、喹诺酮药、环丙沙星、诺氟沙星、四环素、红霉素、阿米卡星、2,4,4'-三氯-2'-羟基二苯醚、3,4,4'-三氯二苯基脲、苯氧基乙醇、苯氧基丙醇、苯氧基异丙醇、强力霉素、卷曲霉素、氯己定、氯四环素、氧四环素、克林霉素、乙胺丁醇、羟乙基磺酸去氧苯比妥、甲硝唑、喷他脒、庆大霉素、卡那霉素、林可霉素、甲烯土霉素、六甲基四胺、米诺环素、新霉素、奈替米星、巴龙霉素、链霉素、妥布霉素、咪康唑、盐酸四环素、红霉素、红霉素锌、依托红霉素,红霉素硬脂酸、硫酸阿米卡星、盐酸强力霉素、硫酸卷曲霉素、葡萄糖酸氯已定、盐酸氯已定、盐酸氯四环素、盐酸氧四环素、盐酸克林霉素、盐酸乙胺丁醇、盐酸甲硝唑、盐酸喷他脒、硫酸庆大霉素、硫酸卡那霉素、盐酸林可霉素、盐酸甲烯土霉素、马尿酸六甲基四胺、杏仁酸六甲基四胺、盐酸米诺环素、硫酸新霉素、硫酸奈替米星、硫酸巴龙霉素、硫酸链霉素、硫酸妥布霉素、盐酸咪康唑、酮康唑、盐酸金刚烷胺、硫酸金刚烷胺、吡啶酮乙醇胺盐、对氧间二甲酚、制霉菌素、托萘酯、羟基吡啶硫酮锌和克霉唑。
不受理论的束缚，据信本发明的组合物令人惊奇地提供抗微生物有益效果和降低刺激。据信加到这些组合物中的吡啶硫酮锌提供减少刺激的协同有益效果，同时提供抗微生物有益效果。由这些组合物提供的各种有益效果的独特组合产生了改进的剃刮体验。
锌盐
本发明的私密清洁产品和/或剃刮制剂任选地包含有效量的锌盐。本发明的优选实施方案包含有效量的锌盐，在25℃下按重量计，所述锌盐在组合物中的水溶解度低于约25%，更优选低于约20%，更优选低于约15%。本发明的优选实施方案包含0.001％至10％；更优选0.01%至5%；还更优选0.1%至3%的锌盐。
在一个优选实施方案中，所述锌盐的平均粒度为100纳米至30微米。
在某些实施方案中，有用的锌盐实例包括下列：锌铝、碳酸锌、氧化锌和含氧化锌材料（如菱锌矿）、锌磷酸盐（如正磷酸盐和焦磷酸盐）、硒化锌、硫化锌、硅酸锌（如正硅酸锌和间硅酸锌）、氟硅酸锌、硼酸锌、氢氧化锌和羟基硫酸锌、含锌的层状材料以及它们的组合。
在含抗刺激剂和锌盐的各种实施方案中，锌盐和抗刺激剂的优选比例为5:100至5:1；更优选2:10至3:1；还更优选1:2至2:1。
止汗剂/除臭剂组合物
本发明的和私密清洁产品一起使用的任选的止汗剂和除臭剂物质是旨在被局部施用到腋下或其它皮肤适宜区域的组合物。术语“止汗剂活性物质”和“除臭剂活性物质”具体地是指能防止或消除恶臭和/或汗湿的局部给药物质。
止汗剂活性物质
在本发明中采用的止汗剂组合物包含适于涂敷到人的皮肤上的止汗剂活性物质。止汗剂活性物质可溶解于止汗剂组合物中，或者也可作为未溶解的或沉淀的固体悬浮。所述止汗剂组合物中的止汗剂活性物质的浓度应当能够通过所选择的止汗剂组合物来充分提供期望的气味和湿度控制。
本发明的止汗剂组合物可被配制成任何已知的或换句话讲有效的产品形式以用于将止汗剂或除臭剂活性物质局部施用到期望的皮肤部位。此类产品形式的非限制性实例包括液体（如气溶胶、喷雾剂、涂抹品），固体（如凝胶状固体、无形固体、固体蜡条），半固体（霜膏、软固体、乳液）等。例如，本发明的止汗剂组合物可为半固体或固体。
所述止汗剂产品一般储存在合适的包装或施用装置中或从所述合适的包装或施用装置中分配。例如，包装或施用装置可为一种具有小孔的施用穹顶的霜膏分配器等。这些包装应当足够密封以避免施用前挥发物的过度挥发。
本文的止汗剂组合物包含止汗剂活性物质，按所选的止汗剂组合物的重量计，其浓度为约0.5%至约60%，优选约0.5%至约50%，更优选约5%至约35%。所有此类重量百分数都是基于无水金属盐而计算的，不包括水和其它络合剂，如甘氨酸、甘氨酸盐或其它络合剂。
本文的止汗剂组合物中使用的止汗剂活性物质包括任何化合物、组合物或其它具有止汗活性的材料。优选止汗剂活性物质包括收敛性金属盐，特别是无机和有机的铝盐、锆盐和锌盐，以及它们的混合物。尤其优选是铝盐和锆盐，例如铝的卤化物、铝的羟基卤化物、锆的卤氧化物、锆的羟基卤化物、以及它们的混合物。
止汗剂活性物质可被配制为呈分散的固体颗粒形式的固体微粒，所述颗粒具有小于约100微米，更优选约2微米至约50微米，甚至更优选约0.4微米至约40微米的优选平均粒度或直径。
本文的止汗剂组合物可包含溶解的止汗剂活性物质，优选地溶解的止汗剂活性物质存在于无水系统中。止汗剂组合物中的溶解的止汗剂活性物质的浓度按所选的止汗剂组合物的重量计（重量百分数是基于无水金属盐而计算的，不包括水和其它络合剂，如甘氨酸，甘氨酸盐或其它络合剂）优选地在约0.1%至35%，更优选约0.5%至约25%，甚至更优选约1%至约17%，甚至更优选约6%至约17%的范围内。
除臭剂活性物质
用于本发明的施用装置中的除臭剂组合物包含除臭剂活性物质，按所选的除臭剂组合物的重量计，其浓度在约0.001%至约50%，优选约0.01%至约20%，更优选约0.1%至约10%，甚至更优选约0.1%至约5%的范围内。这些除臭剂活性物质能包括任何已知的或换句话讲安全和有效的、适于局部施用在到人类皮肤上的除臭剂活性物质。
本文所述的适用于除臭剂组合物中的除臭剂活性物质包含任何局部施用的材料，所述材料已知用于或换句话讲有效用于防止或消除与出汗相关联的恶臭。这些除臭剂活性物质是典型的抗微生物剂（如杀菌剂、杀真菌剂）、恶臭吸收材料、或它们的组合。
优选除臭剂活性物质是抗微生物剂，其非限制性实例包括鲸蜡基三甲基溴化铵、西吡氯铵、苄基二甲基[2-[2-[4-(1,1,3,3-四甲基丁基)苯氧基]乙氧基]乙基]氯化铵、二异丁基苯氧基乙氧基乙基二甲基苄基氯化铵、N-十二烷基肌氨酸钠、N-palmethyl肌氨酸钠、肌氨酸月桂酯、N-肉豆寇酰甘氨酸、N-十二烷基肌氨酸钾、三甲基氯化铵、乳酸氯羟化铝钠、三乙基柠檬酸、三鲸蜡基甲基氯化铵、2,4,4'-三氯-2'-羟基二苯醚（三氯生）、3,4,4'-三氯碳酰替苯胺（三氯卡班）、双氨基烃基酰胺如L-赖氨酸十六酰胺、柠檬酸、水杨酸和piroctose的重金属盐，特别是锌盐、及其酸，吡啶硫酮重金属盐，特别是吡啶硫酮锌、苯酚硫酸锌，金合欢醇，以及它们的组合。
其它除臭剂活性物质包括气味吸收物质，如碳酸盐和碳酸氢盐，包括碱金属碳酸盐和碳酸氢盐，四烷基碳酸铵/四烷基碳酸氢铵。优选是此类气味吸收物质的钠盐和钾盐。
本发明的除臭剂组合物可被配制为任何已知的或换句话讲有效的产品形式以用于将止汗剂或除臭剂局部施用到期待的皮肤部位。此类产品形式的非限制性实例包括液体（如气溶胶、喷雾剂、涂抹品）、固体（如凝胶状固体、无形固体、固体蜡条）、半固体（霜膏、软固体、乳液）等。例如，本发明的止汗剂组合物可为半固体或固体。
所述除臭剂产品一般储存在合适的包装或施用装置中或从所述合适的包装或施用装置中分配。例如，包装或施用装置可为一种具有小孔的施用穹顶的霜膏分配器等。这些包装应当足够密封以避免施用前挥发物的过度挥发。
使用方法
所述私密清洁产品和剃刮制剂的预期使用方法有许多种。在一个实施方案中，预期所述私密清洁产品被施用和直接用于剃刮。因此，单一成分提供了抗刺激有益效果和抗微生物有益效果，同时适合用于去除毛发。因此在该实施方案中，所述私密清洁产品包含恶臭活性物质。在剃刮步骤结束后，优选的是进行一个在私密区的冲洗步骤以去除剃刮步骤中任何残留的私密清洁产品和/或毛发。
也可预期施用私密清洁产品、冲洗私密清洁产品并施用剃刮制剂。在该实施方案中，剃刮步骤发生在私密区施用剃刮制剂后。重要的是，恶臭活性物质可被包含在私密清洁产品中、剃刮制剂中、或组合中。在施用剃刮制剂后，开始剃刮步骤。在剃刮步骤结束后，优选进行一个在私密区的冲洗步骤以去除剃刮步骤中任何残留的私密清洁产品和/或毛发。
预期所述私密清洁产品和/或剃刮制剂将与止汗剂或除臭剂组合使用。例如，在私密清洁产品被施用和冲洗后，止汗剂或除臭剂可在淋浴结束后一小时内施用。预期干燥步骤可发生在止汗剂或除臭剂的冲洗步骤和施用步骤之间。此类干燥步骤可以通过空气干燥（热空气或室温空气）或用毛巾擦干或替代布擦干来完成。普通技术人员很容易了解用于对私密区进行干燥的机制。
功效的进一步提高可通过在睡眠周期之前实施本发明来完成，虽然也考虑在睡眠周期之后施用。一般来讲，睡眠周期包括至少约一小时，至少约两小时，至少约四小时或至少约八小时的休息时段。通常，睡眠周期从日落开始到日出结束。然而预期个人可以利用非传统睡眠周期。
然而不限于上述的处理方案，本发明人发现，此类处理方案可通过在较长时间内有效地减少或抑制出汗而有助于治疗多汗症。
联合包装
本发明的产品可以单个地包装到独立的容器中，或者它们可以整体的形式被包装在一起以便一起出售和购买。文字和/或图释说明被包括在单独包装中或整体包装中以指导消费者何时及如何使用本产品。另外，所述产品或所述多个产品可以包装到次级包装里，其中外包容器体现了其内公开的产品。
应当理解，在整个说明书中给出的每一最大数值限度均包括每一较低数值限度，就像这样的较低数值限度在本文中明确地写出一样。本说明书全文中给出的每一最小数值限度均包括每一较高数值限度，就像这样的较高数值限度在本文中明确写出的一样。本说明书全文中给出的每一数值范围均包括属于上述较宽数值范围的每一较窄数值范围，就像这样的较窄数值范围在本文中明确写出的一样。
除非另外指明，本文的说明书、实施例和权利要求书中的所有份数、比例和百分数均按重量计，并且所有的数值范围均使用本领域给出的常规精确度。
本文所公开的量纲和值不旨在被理解为严格地限于所述的精确值。相反，除非另外指明，每个这样的量纲是指所引用的数值和围绕该数值的功能上等同的范围。例如，公开为“40mm”的量纲旨在表示“约40mm”。
本文引用的所有文件在相关的部分以引用方式并入本文；引用的任何文件不能被解释为承认是针对本发明的现有技术。当本书面文献中术语的任何含义或定义与以引用方式并入本文的文献中的术语的任何含义或定义冲突时，将以赋予本书面文献中的术语的含义或定义为准。
除非另外说明，冠词“一个”、“一种”及“所述”是指“一种或多种”。
尽管已用具体实施方案来说明和描述了本发明，但对于本领域的技术人员显而易见的是，在不脱离本发明的精神和保护范围的情况下可作出许多其它的改变和变型。因此，随附权利要求书中旨在涵盖本发明范围内的所有这些改变和变型。
Claims (12)
1.一种用于降低对私密区的刺激的方法，所述方法包括：
将私密清洁产品施用到所述私密区；
将所述私密清洁产品从所述私密区冲洗掉；
将剃刮制剂施用到所述私密区；以及
剃刮所述私密区；
其中：所述私密清洁产品和所述剃刮制剂中的至少一种包含恶臭活性物质。
2.如权利要求1所述的方法，其中所述恶臭活性物质包含吡啶硫酮锌。
3.如权利要求2所述的方法，其中按所述私密清洁产品的重量计，所述吡啶硫酮锌以约0.001%至约10%存在。
4.如任一项前述权利要求所述的方法，其中所述私密清洁产品进一步包含锌盐。
5.如权利要求4所述的方法，其中所述锌盐包括氧化锌。
6.如权利要求4或5所述的方法，其中按所述私密清洁产品的重量计，所述锌盐以约0.001%至10%存在。
7.一种用于降低对私密区的刺激的方法，所述方法包括：
将私密清洁产品施用到所述私密区，其中所述私密清洁产品包含恶臭活性物质；
剃刮所述私密区；以及
冲洗所述私密区。
8.如权利要求7所述的方法，其中所述恶臭活性物质包含吡啶硫酮锌。
9.如权利要求7或8所述的方法，其中按所述私密清洁产品的重量计，所述吡啶硫酮锌以约0.001%至约10%存在。
10.如权利要求7-9中的任一项所述的方法，其中所述私密清洁产品进一步包含锌盐。
11.如权利要求10所述的方法，其中所述锌盐包括氧化锌。
12.如权利要求10或11的方法，其中按所述私密清洁产品的重量计，所述锌盐以约0.001%至10%存在。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30513210P | 2010-02-16 | 2010-02-16 | |
| US61/305,132 | 2010-02-16 | ||
| PCT/US2011/025024 WO2011103147A2 (en) | 2010-02-16 | 2011-02-16 | Method for providing maximum malodor and irritation control |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102781413A true CN102781413A (zh) | 2012-11-14 |
Family
ID=44368781
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011800094395A Pending CN102781413A (zh) | 2010-02-16 | 2011-02-16 | 用于提供最大程度的恶臭和刺激控制的方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US8978666B2 (zh) |
| EP (1) | EP2536389A2 (zh) |
| CN (1) | CN102781413A (zh) |
| MX (1) | MX2012009491A (zh) |
| WO (1) | WO2011103147A2 (zh) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9173826B2 (en) | 2010-02-16 | 2015-11-03 | The Procter & Gamble Company | Porous, dissolvable solid substrate and surface resident coating comprising a zync pyrithione |
| MX2014001896A (es) | 2011-08-15 | 2014-05-27 | Procter & Gamble | Metodos para el cuidado personal. |
| MX2014013686A (es) | 2012-05-11 | 2015-07-06 | Procter & Gamble | Composiciones para la limpieza personal que comprenden piritiona de zinc. |
| WO2014169464A1 (en) | 2013-04-18 | 2014-10-23 | The Procter & Gamble Company | Personal care compositions containing zinc pyrithione and zinc-phosphonate complex |
| CA2901658A1 (en) | 2013-03-14 | 2014-09-18 | The Procter & Gamble Company | Bar soap compositions containing zinc pyrithione and a zinc-pyridine oxide complex |
| US10201481B2 (en) | 2014-03-07 | 2019-02-12 | The Procter & Gamble Company | Personal care compositions and methods of making same |
| WO2016179446A1 (en) | 2015-05-06 | 2016-11-10 | The Procter & Gamble Company | Methods of cosmetically treating skin conditions with a cosmetic personal cleansing composition |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4565693A (en) * | 1981-11-09 | 1986-01-21 | Colgate-Palmolive Company | Deodorant composition |
| DE19537509A1 (de) * | 1995-09-27 | 1997-04-10 | Egsto Pharm Pharmazeutische Pr | Hautpflegemittel |
| CN1414846A (zh) * | 1999-06-25 | 2003-04-30 | 宝洁公司 | 局部抗微生物组合物 |
| US20030104021A1 (en) * | 1996-10-07 | 2003-06-05 | Veronique Burnier | High electrolyte content W/O emulsions for treating irritated/sensitive skins |
| US6774096B1 (en) * | 2003-10-09 | 2004-08-10 | Colgate-Palmolive Co. | Zinc oxide containing surfactant solution |
| CN101287441A (zh) * | 2005-07-25 | 2008-10-15 | 巴斯夫欧洲公司 | 皮肤用化妆品制剂 |
Family Cites Families (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3235455A (en) | 1962-02-09 | 1966-02-15 | Procter & Gamble | Synergistic antibacterial compositions |
| US3281366A (en) | 1962-02-09 | 1966-10-25 | Procter & Gamble | Synergistic antibacterial compositions |
| US3412033A (en) | 1963-09-05 | 1968-11-19 | Vanderbilt Co R T | Germicidal detergent compositions |
| US3725547A (en) | 1970-10-08 | 1973-04-03 | Procter & Gamble | Synergistic antibacterial combination |
| NZ194560A (en) | 1979-08-10 | 1984-05-31 | Unilever Ltd | Deodorant compositions containing zinc carbonate |
| US4379753A (en) | 1980-02-07 | 1983-04-12 | The Procter & Gamble Company | Hair care compositions |
| US4345080A (en) | 1980-02-07 | 1982-08-17 | The Procter & Gamble Company | Pyridinethione salts and hair care compositions |
| EP0034385B1 (en) | 1980-02-07 | 1984-09-12 | THE PROCTER & GAMBLE COMPANY | Zinc-pyridinethione salts, a process for making thereof and hair care compositions containing them |
| EP0093541A3 (en) | 1982-04-29 | 1984-09-12 | Beecham Group Plc | Antidandruff compositions |
| US5037818A (en) | 1982-04-30 | 1991-08-06 | Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. | Washing composition for the hair |
| GB8407999D0 (en) | 1984-03-28 | 1984-05-10 | Procter & Gamble Ltd | Hair care compositions |
| GB8507349D0 (en) | 1985-03-21 | 1985-05-01 | Procter & Gamble Ltd | Hair care compositions |
| GB8523889D0 (en) | 1985-09-27 | 1985-10-30 | Procter & Gamble | Hair treatment |
| US4714563A (en) | 1986-07-18 | 1987-12-22 | The Procter & Gamble Company | Antimicrobial toilet bars |
| EP0285388A3 (en) | 1987-04-01 | 1989-01-11 | The Procter & Gamble Company | Shampoo compositions |
| US5104645A (en) | 1990-02-02 | 1992-04-14 | The Proctor & Gamble Company | Antidandruff shampoo compositions |
| GB9016525D0 (en) | 1990-07-27 | 1990-09-12 | Unilever Plc | Cosmetic composition |
| ES2068034T3 (es) | 1991-04-05 | 1995-04-01 | Procter & Gamble | Composiciones de champues acondicionadoras del cabello con agente acondicionador del tipo de silicona. |
| GB9226684D0 (en) | 1992-12-22 | 1993-02-17 | Unilever Plc | Deodorant compositions |
| GB9226685D0 (en) | 1992-12-22 | 1993-02-17 | Unilever Plc | Deodorant compositions |
| US5573699A (en) | 1993-09-30 | 1996-11-12 | Church & Dwight Co., Inc. | Deodorant soap or detergent composition |
| US5540860A (en) | 1994-02-28 | 1996-07-30 | Olin Corporation | Process for preparing copper pyrithione |
| US5886031A (en) | 1997-01-27 | 1999-03-23 | Pacific Corporation | Hair-care cosmetic compositions having dandruff formation-suppressing effect |
| US6017936A (en) | 1997-03-14 | 2000-01-25 | Arch Chemicals, Inc. | Method for producing particles of pyrithione salts and particles so produced |
| US6162446A (en) | 1998-03-11 | 2000-12-19 | Arch Chemicals, Inc. | In-situ generation of zinc pyrithione in personal care compositions |
| US6017562A (en) | 1997-04-28 | 2000-01-25 | Arch Chemicals, Inc. | Non-spherical and non-platelet crystalline forms of pyrithione salts |
| US6242007B1 (en) | 1997-04-28 | 2001-06-05 | Arch Chemicals, Inc. | Non-spherical and non-platelet forms of pyrithione salts and methods of making same |
| US6015547A (en) | 1997-10-27 | 2000-01-18 | Church & Dwight Co., Inc. | Stable solution of zinc ions and bicarbonate and/or carbonate ions |
| GB9725013D0 (en) | 1997-11-26 | 1998-01-28 | Unilever Plc | Washing composition |
| US6096297A (en) | 1998-02-04 | 2000-08-01 | Unilever Home & Personal Care Usa | Underarm cosmetic compositions with lower alkyl acetate |
| US6465015B1 (en) | 1998-02-24 | 2002-10-15 | Arch Chemicals, Inc. | Sonic method of enhancing chemical reactions to provide uniform, non-agglomerated particles |
| GB9813640D0 (en) | 1998-06-24 | 1998-08-26 | Unilever Plc | Antimicrobial hair treatment composition |
| AU2170200A (en) | 1998-12-15 | 2000-07-03 | Procter & Gamble Company, The | Methods of absorbing body odors using silica containing body powders |
| US6682724B2 (en) | 1999-02-23 | 2004-01-27 | Arch Chemcials, Inc. | Sonic method of enhancing chemical reactions to provide uniform, non-agglomerated particles |
| US6432432B1 (en) | 1999-03-05 | 2002-08-13 | Arch Chemicals, Inc. | Chemical method of making a suspension, emulsion or dispersion of pyrithione particles |
| US6451300B1 (en) | 1999-05-03 | 2002-09-17 | The Procter & Gamble Company | Anti-dandruff and conditioning shampoos containing polyalkylene glycols and cationic polymers |
| US6649155B1 (en) | 1999-05-03 | 2003-11-18 | The Procter & Gamble Company | Anti-dandruff and conditioning shampoos containing certain cationic polymers |
| US6974569B2 (en) | 1999-05-03 | 2005-12-13 | The Procter & Gamble Company | Shampoos providing a superior combination anti-dandruff efficacy and condition |
| US7026308B1 (en) * | 1999-06-25 | 2006-04-11 | The Procter & Gamble Company | Topical anti-microbial compositions |
| US7674785B2 (en) | 2000-06-22 | 2010-03-09 | The Procter & Gamble Company | Topical anti-microbial compositions |
| GB0015723D0 (en) | 2000-06-27 | 2000-08-16 | Unilever Plc | Compositions containing a metal pyrithione |
| US6673756B2 (en) | 2000-09-20 | 2004-01-06 | Symrise Gmbh & Co. Kg | Multiphase soaps |
| WO2003026608A1 (en) | 2001-09-26 | 2003-04-03 | The Procter & Gamble Company | Topical compositions containing fluid-absorbent solids and adhesive fluids |
| TWI306765B (en) | 2002-03-29 | 2009-03-01 | Shiseido Co Ltd | Composite particles and cosmetic materials containing the same |
| ES2601463T3 (es) | 2002-04-22 | 2017-02-15 | The Procter & Gamble Company | Composiciones para la higiene personal que comprenden un material que contiene cinc en una composición tensioactiva acuosa |
| US8491877B2 (en) | 2003-03-18 | 2013-07-23 | The Procter & Gamble Company | Composition comprising zinc-containing layered material with a high relative zinc lability |
| US9381148B2 (en) | 2003-03-18 | 2016-07-05 | The Procter & Gamble Company | Composition comprising particulate zinc material with a high relative zinc lability |
| US9381382B2 (en) | 2002-06-04 | 2016-07-05 | The Procter & Gamble Company | Composition comprising a particulate zinc material, a pyrithione or a polyvalent metal salt of a pyrithione and a gel network |
| US20080206355A1 (en) | 2002-06-04 | 2008-08-28 | The Procter & Gamble Company | Composition comprising a particulate zinc material, a pyrithione or a polyvalent metal salt of a pyrithione and a synthetic cationic polymer |
| US20050202984A1 (en) | 2003-03-18 | 2005-09-15 | Schwartz James R. | Composition comprising zinc-containing layered material with a high relative zinc lability |
| US20040161435A1 (en) | 2003-02-14 | 2004-08-19 | Gupta Shyam K. | Skin Firming Anti-Aging Cosmetic Mask Compositions |
| US20040213751A1 (en) | 2003-03-18 | 2004-10-28 | Schwartz James Robert | Augmentation of pyrithione activity or a polyvalent metal salt of pyrithione activity by zinc-containing layered material |
| US20040191331A1 (en) | 2003-03-18 | 2004-09-30 | The Procter & Gamble Company | Composition comprising particulate zinc materials having a defined crystallite size |
| US8980235B2 (en) | 2003-09-30 | 2015-03-17 | Arch Chemicals, Inc. | Coated metal pyrithione particles for treatment of microorganisms |
| US20050244352A1 (en) | 2004-04-15 | 2005-11-03 | Cyril Lemoine | Cosmetic composition of the water-in-oil emulsion type comprising a deodorant active salt and a polyolefin-derived emulsifier comprising at least one polar part |
| GB2414666B (en) | 2004-06-03 | 2009-01-07 | James Steven Brown | Sanitizing composition and method of preparation |
| JP2006176675A (ja) | 2004-12-22 | 2006-07-06 | Riken Koryo Kogyo Kk | 洗浄剤用消臭性配合剤及び洗浄剤組成物 |
| US20070009463A1 (en) | 2005-07-06 | 2007-01-11 | Niebauer Michael F | Rheology profile for a personal care composition |
| US20070009472A1 (en) | 2005-07-06 | 2007-01-11 | Niebauer Michael F | Personal care compositions comprising a non-binding thickener with a metal ion |
| EP2952095A1 (en) | 2005-10-25 | 2015-12-09 | Dow Global Technologies LLC | Antimicrobial composition and method |
| US11717533B2 (en) | 2005-12-22 | 2023-08-08 | Swiss-American Cdmo Llc | Zinc composition and their use in anti-microbial applications |
| US20120195944A9 (en) | 2009-08-12 | 2012-08-02 | Amy Michelle Capretta | Rinse-Off Care Products and Consumer Product Line-ups Comprising Same |
| EP2536385A2 (en) | 2010-02-16 | 2012-12-26 | The Procter & Gamble Company | A post foaming gel composition comprising an anti-irritation agent |
| US9173826B2 (en) | 2010-02-16 | 2015-11-03 | The Procter & Gamble Company | Porous, dissolvable solid substrate and surface resident coating comprising a zync pyrithione |
| MX2012009492A (es) | 2010-02-16 | 2012-08-31 | Procter & Gamble | Metodo para proporcionar control maximo del mal olor y la transpiracion. |
| WO2011103173A2 (en) | 2010-02-17 | 2011-08-25 | The Procter & Gamble Company | Non-aerosol personal care compositions comprising an anti-irritation agent |
| CN103476554A (zh) | 2010-10-27 | 2013-12-25 | 吉列公司 | 包含不起泡的保湿组合物的组合物分配装置 |
| US9119796B2 (en) | 2011-02-28 | 2015-09-01 | The Gillette Company | Razor comprising a molded shaving aid composition comprising a pyrithione source |
| US20120219610A1 (en) | 2011-02-28 | 2012-08-30 | Smith Iii Edward Dewey | Bar Compositions Comprising Platelet Zinc Pyrithione |
| JP2014513076A (ja) | 2011-04-04 | 2014-05-29 | ザ プロクター アンド ギャンブル カンパニー | パーソナルケア物品 |
| EP2537511B1 (en) | 2011-06-24 | 2017-02-01 | The Gillette Company LLC | Hair removal device comprising erodable moisturizer |
| MX2014001896A (es) | 2011-08-15 | 2014-05-27 | Procter & Gamble | Metodos para el cuidado personal. |
| EP2744341A2 (en) | 2011-08-15 | 2014-06-25 | The Procter and Gamble Company | Personal care compositions having dried zinc pyrithione-polymer aggregates |
| US20130045907A1 (en) | 2011-08-15 | 2013-02-21 | Anthony Charles Lanzalaco | Methods of Reducing Odor |
| EP2744339A2 (en) | 2011-08-15 | 2014-06-25 | The Procter and Gamble Company | Personal care compositions having dried zinc pyrithione |
| US20130045284A1 (en) | 2011-08-15 | 2013-02-21 | Qing Stella | Methods of Enhancing Skin Hydration and Treating Non-Diseased Skin |
| CA2844302C (en) | 2011-08-15 | 2017-07-04 | The Procter & Gamble Company | Methods of enhancing skin hydration and improving non-diseased skin |
| US20130045256A1 (en) | 2011-08-16 | 2013-02-21 | James Robert Schwartz | Shave preparations comprising an anti-irritation agent |
| WO2013025893A1 (en) | 2011-08-16 | 2013-02-21 | The Gillette Company | Personal care compositions comprising an anti-irritation agent |
| US20130042482A1 (en) | 2011-08-16 | 2013-02-21 | Valerie Jean Bradford | Skin Engaging Member Comprising An Anti-Irritation Agent |
| US20130045257A1 (en) | 2011-08-16 | 2013-02-21 | Ali Alwattari | Aerosol shave composition comprising a hydrophobical agent forming at least one microdroplet and an anti-irritation agent |
| MX2014001892A (es) | 2011-08-16 | 2014-05-27 | Gillette Co | Dispositivo dispensador de composiciones que comprende una composicion hidratante. |
| US20130048005A1 (en) | 2011-08-22 | 2013-02-28 | Edward Dewey Smith, III | Skin Care Regimen Comprising At Least One Composition Comprising A Pyrithione Source |
| MX2014013686A (es) | 2012-05-11 | 2015-07-06 | Procter & Gamble | Composiciones para la limpieza personal que comprenden piritiona de zinc. |
-
2011
- 2011-02-16 US US13/028,890 patent/US8978666B2/en not_active Expired - Fee Related
- 2011-02-16 MX MX2012009491A patent/MX2012009491A/es not_active Application Discontinuation
- 2011-02-16 EP EP11706103A patent/EP2536389A2/en not_active Withdrawn
- 2011-02-16 CN CN2011800094395A patent/CN102781413A/zh active Pending
- 2011-02-16 WO PCT/US2011/025024 patent/WO2011103147A2/en active Application Filing
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4565693A (en) * | 1981-11-09 | 1986-01-21 | Colgate-Palmolive Company | Deodorant composition |
| DE19537509A1 (de) * | 1995-09-27 | 1997-04-10 | Egsto Pharm Pharmazeutische Pr | Hautpflegemittel |
| US20030104021A1 (en) * | 1996-10-07 | 2003-06-05 | Veronique Burnier | High electrolyte content W/O emulsions for treating irritated/sensitive skins |
| CN1414846A (zh) * | 1999-06-25 | 2003-04-30 | 宝洁公司 | 局部抗微生物组合物 |
| US6774096B1 (en) * | 2003-10-09 | 2004-08-10 | Colgate-Palmolive Co. | Zinc oxide containing surfactant solution |
| CN101287441A (zh) * | 2005-07-25 | 2008-10-15 | 巴斯夫欧洲公司 | 皮肤用化妆品制剂 |
Also Published As
| Publication number | Publication date |
|---|---|
| MX2012009491A (es) | 2012-08-31 |
| US20110197907A1 (en) | 2011-08-18 |
| US8978666B2 (en) | 2015-03-17 |
| WO2011103147A2 (en) | 2011-08-25 |
| WO2011103147A3 (en) | 2012-05-03 |
| EP2536389A2 (en) | 2012-12-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102781413A (zh) | 用于提供最大程度的恶臭和刺激控制的方法 | |
| CN103002862A (zh) | 用于提供最大程度的恶臭和出汗控制的方法 | |
| RU2465891C2 (ru) | Антибактериальные композиции, продукты и способы их применения | |
| CA2833030C (en) | Sodium hypochlorite-based body wash compositions | |
| US20150148425A1 (en) | Antimicrobial composition exhibiting increased efficacy | |
| US10251822B2 (en) | Methods and compositions for treating cutaneous fungal infections | |
| US7704530B2 (en) | Antimicrobially treated material and methods of preventing coloring thereof | |
| AU2018382466A1 (en) | Propanediol monoacetate mononitrate | |
| JP4743704B2 (ja) | 腋臭菌用抗菌剤、並びに該抗菌剤を含有する腋臭防止剤及び皮膚外用剤 | |
| AU2013361865B2 (en) | Improved protection against body odor | |
| US20170246095A1 (en) | Topical sanitizer that includes avenanthramides | |
| JP7121400B2 (ja) | 化粧品洗浄剤製品およびその使用 | |
| WO2024074854A1 (en) | Product for reduction of body odours and application procedure | |
| Siquet et al. | Antibacterial agents and preservatives | |
| EP1362885B1 (en) | Antimicrobially treated material and methods of preventing coloring thereof | |
| US20200375190A1 (en) | Alkyl Dimethyl Organosilane Quaternaries in Persistent Systems and Methods | |
| KR102474984B1 (ko) | 항균 및 소취 효과가 우수한 화장료 조성물 | |
| JP2018052891A (ja) | 皮膚常在菌制御用塗布剤 | |
| JP2006335761A (ja) | 長期間作用する脱臭組成物 | |
| JP2006176446A (ja) | 頭皮頭髪用組成物 | |
| JP2012224609A (ja) | 皮膚刺激性の無い新規殺菌・抗カビ・保湿・抗炎症剤 | |
| WO2017189972A1 (en) | Beard care composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20121114 |